A Study to Assess the Use of Methylone in the Treatment of PTSD
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety, tolerability, and efficacy of methylone in adults with
PTSD. The study will be conducted in two parts.
- Part A is open-label and will enroll up to 15 participants with PTSD
- Part B is randomized (1:1), double-blind, placebo-controlled and will enroll up to 64
participants with PTSD
Eligible participants will enter a 4-week Treatment Period where they will receive methylone
once weekly for 4 weeks (4 treatment sessions). Following the Treatment Period, participants
will enter a 6-week Follow-up Period which includes 3 reflection visits (Week 4, 5, and 6)
and a final study visit at Week 10.